Gladstone Institutes

Global CRISPR and CRISPR-associated (Cas) Genes Market Report 2022-2027 - Growing Investments in R&D Programs by Biotechnology Companies and Non-Profit Organizations - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022
Biotechnology, Genetics, Health, COVID-19, Agriculture, FDA, Addgene, UC, USD, Biotechnology, Global, University of California, Berkeley, Sherlock, Research, Adoption, Merck Group, CRISPR Therapeutics, CRISPR, The CRISPR Journal, Bill & Melinda Gates Foundation, Laboratory, COVID-19, San Francisco, Plasmid, HIV, Bacteria, University of California, San Francisco, Bill, Investment, CAGR, Technology, Gene editing, University, Genome, Immunology, Organization, Gladstone Institutes, Genetics, Medicine, Time, Editas Medicine, Thermo Fisher Scientific, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Therapy, Bangladesh Technical Education Board, Vaccine, Pharmaceutical industry, Growth

The "CRISPR and CRISPR-associated (Cas) Genes Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CRISPR and CRISPR-associated (Cas) Genes Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • Initiatives such as these are expected to have a positive effect on the market for CRISPR and CRISPR-associated (Cas) Genes.
  • Furthermore, the growing investments in research and development programs by biotechnology companies and non-profit organizations is boosting the market growth.
  • The funding was expected to help in the further development of CRISPR diagnostics and next-generation CRISPR products for the company.

Finding HIV's Sweet Spot

Retrieved on: 
Tuesday, July 5, 2022
Cell, Memory, Wistar Institute, National, Media contacts database, Communication, University of California, San Francisco, Tcell, Roan, Protein, Tissue, AIDS, Biomarker, Infection, Population, UM1, Center, Blood, HIV, SAN, Bias, Fucose, CyTOF, Moore v. Regents of the University of California, Technology, University, Sugar, Antibody, Doctor of Philosophy, Virus, Urology, Cell biology, Gladstone Institutes, HIV/AIDS, Research, Severe acute respiratory syndrome coronavirus 2, HIV/AIDS research, Multimedia, Lectin, Collection, Vaccine, Pharmaceutical industry, Antibiotics, ELife, William Ewart Gladstone

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been trying to identify the specific cells that the virus prefers to infect and hide in. They know that HIV favors a special type of immune cells called memory CD4 T cells. But these cells come in many flavors, and it has been difficult to ascertain exactly what makes one type of memory CD4 T cell more attractive to HIV than another.

Key Points: 
  • Together, the scientists uncovered surprisingly different sugar patterns on different immune cells, and an intriguing interplay between HIV and the sugars coating CD4 Tcells.
  • The work also showcases a new technique for studying individual cells from large populations that could lead to a more detailed picture of cellular diversity.
  • Encouraged by this finding, the scientists next applied CyTOF-Lec to CD4 Tcells that they had first exposed to HIV in the lab.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

Retrieved on: 
Thursday, June 16, 2022
Cardiology, Medical Supplies, Biotechnology, Manufacturing, Construction & Property, Health, General Health, Pharmaceutical, Other Manufacturing, Genetics, Other Construction & Property, University of Texas Southwestern Medical Center, Industry, Security (finance), Gladstone Institutes, FDA, Securities Exchange Act of 1934, Therapy, COVID-19, Quality control, Culture, Safety, Science, AAV, MYBPC3, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Beckman Center for Molecular and Genetic Medicine, Degenerative disease, Precision medicine, Genetic engineering, U.S. Securities and Exchange Commission, Research, PKP2, Investigational New Drug, Securities Act of 1933, HCM, Clinical trial, Marketing, University, Drug Quality and Security Act, NASDAQ, IND, ARVC, Patient, Food, CGMP, Bioreactor, Multimedia, Pharmaceutical industry, Tenaya

The operational launch of Tenayas Genetic Medicines Manufacturing Center represents an important milestone as we prepare to advance our robust pipeline of potentially first-in-class cardiovascular therapies into initial clinical studies.

Key Points: 
  • The operational launch of Tenayas Genetic Medicines Manufacturing Center represents an important milestone as we prepare to advance our robust pipeline of potentially first-in-class cardiovascular therapies into initial clinical studies.
  • Tenayas Genetic Medicines Manufacturing Center is designed to meet regulatory requirements for production of AAV gene therapies from discovery through commercialization under Current Good Manufacturing Practice (cGMP) standards.
  • Tenaya completed customization of approximately half of the 94,000 square foot facility to incorporate manufacturing suites and labs, office space and storage.
  • The Genetic Medicines Manufacturing Center is staffed by a growing in-house team with expertise in all aspects of gene therapy manufacture, including process development, analytical development, quality assurance and quality control.

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

Retrieved on: 
Friday, May 20, 2022
Research, FDA, Clinical Trials, Cardiology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Heart failure with preserved ejection fraction, University of Texas Southwestern Medical Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Degenerative disease, U.S. Securities and Exchange Commission, European Society of Cardiology, Patient, NASDAQ, Therapy, Clinical trial, Cardiac fibrosis, COVID-19, Marketing, Gladstone Institutes, FDA, Securities Act of 1933, Securities Exchange Act of 1934, IND, Precision medicine, Industry, University, Heart failure, Drug Quality and Security Act, Security (finance), ESC, HDAC6, Investigational New Drug, Pharmaceutical industry, Tenaya

TN-301 (previously named TYA-11631) is a small molecule HDAC6 inhibitor initially being developed by Tenaya for the potential treatment of heart failure with preserved ejection fraction (HFpEF).

Key Points: 
  • TN-301 (previously named TYA-11631) is a small molecule HDAC6 inhibitor initially being developed by Tenaya for the potential treatment of heart failure with preserved ejection fraction (HFpEF).
  • HFpEF is one of the greatest areas of unmet need in heart disease with more than three million patients in the United States.
  • Tenaya expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second half of 2022.
  • Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease.

"Natural Immunity" from Omicron is Weak and Limited, Study Finds

Retrieved on: 
Wednesday, May 18, 2022
Severe acute respiratory syndrome coronavirus 2, UC, Population, Blood, F31, Infection, Doctor of Philosophy, Centers for Disease Control and Prevention, Multimedia, Natural science, Alpha, Vaccine, Antibody, Vaccination, Nature, Howard Hughes Medical Institute, WA1, George Mason University, COVID-19, Gladstone Institutes, University of California, San Francisco, University of California, Berkeley, Research, Natural reservoir, Mouse, SAN, Mercatus Center, UCSF, Engineering, Immunity, Virus, University, Technology, Biomedical Research, Stockholm Environment Institute US Center, Emergent, Immune system, Animal, National, Globe, Abbott Laboratories, MD, Pharmaceutical industry, William Ewart Gladstone, Omicron, Delta, Virology

SAN FRANCISCO, May 18, 2022 /PRNewswire/ -- In unvaccinated people, infection with the Omicron variant of SARS-CoV-2 provides little long-term immunity against other variants, according to a new study by researchers at Gladstone Institutes and UC San Francisco (UCSF), published today in the journal Nature.

Key Points: 
  • In experiments using mice and blood samples from donors who were infected with Omicron, the team found that the Omicron variant induces only a weak immune response.
  • To find the answer, the team of researchers first examined the effect of Omicron in mice.
  • Compared to an ancestral strain of SARS-CoV-2 and the Delta variant, Omicron led to far fewer symptoms in the mice.
  • Samples from WA1-infected animals could neutralize Alpha and, to a lesser degree, the Beta and Delta virusbut not Omicron.

Throwing Drug Resistance for a Loop

Retrieved on: 
Thursday, May 12, 2022
Severe acute respiratory syndrome coronavirus 2, Communication, CMV, Birth, Degenerative disease, Disease, UC, The Pew Charitable Trusts, Doctor of Philosophy, Infection, Multimedia, Patient, Pioneer Award, Membrane protein, Biophysics, P30, Synthetic biology, Severe cognitive impairment, Media contacts database, Biomedical engineering, New, COVID-19, Gladstone Institutes, University of California, San Francisco, Cell, Cytomegalovirus, NIH, Research, Mouse, SAN, Biomedicine, Center, Biochemistry, Stony Brook University, State, Virus, Orthornavirae, RNA, Ministry of Energy, Transplant, Technology, University, HSV-1, Drug resistance, NIH Director's New Innovator Award, Therapy, Self-destruct, Los Alamos National Laboratory, Protein, National, Cancer, Genetically modified bacteria, Pew, Next, Vaccine, Pharmaceutical industry, William Ewart Gladstone

SAN FRANCISCO, May 12, 2022 /PRNewswire/ -- Viruses in the herpesvirus family are leading causes of birth defects, blindness, and failed organ transplants worldwide. Antiviral drugs can combat these viruses, but patients often develop resistance to the drugs—rendering them ineffective.

Key Points: 
  • Antiviral drugs can combat these viruses, but patients often develop resistance to the drugsrendering them ineffective.
  • "This study shows, for the first time, that feedback circuits can be a drug target to treat viruses.
  • "Antiviral drug resistance is a huge problem that affects millions of people around the world," says Chaturvedi, first author of the new study and research investigator at Gladstone.
  • The scientists realized that if they could develop a drug to disrupt this loop, they could potentially treat CMV infection while avoiding drug resistance.

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 11, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Royal commission, R, University of Texas Southwestern Medical Center, Regulation of tobacco by the U.S. Food and Drug Administration, G&A, Degenerative disease, Food, Survival, Securities and Exchange Commission (Philippines), European Commission, Arrhythmia, Investment, NASDAQ, General Administration of Sport of China, Therapy, HCM, PKP2, Clinical trial, CGMP, COVID-19, Marketing, Gladstone Institutes, FDA, Securities Act of 1933, IND, Securities Exchange Act of 1934, Precision medicine, Industry, Fibrosis, Program, University, MYBPC3, Orphan, Drug Quality and Security Act, Security (finance), Administration, Research and development, Investigational New Drug, Pharmaceutical industry, Online gambling, Tenaya

Tenaya expects to submit an Investigational New Drug (IND) application for TN-201 to the FDA in the second half of 2022.

Key Points: 
  • Tenaya expects to submit an Investigational New Drug (IND) application for TN-201 to the FDA in the second half of 2022.
  • Tenaya presented preclinical data at the Heart Rhythm Societys annual Heart Rhythm 2022 meeting for its investigational PKP2 gene therapy, TN-401.
  • Tenaya expects to submit an IND application for TN-301 to the FDA in the second half of 2022.
  • Net Loss: Net loss for the first quarter ended March 31, 2022, was $31.1 million, or $0.75 per share.

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

Retrieved on: 
Tuesday, May 3, 2022
General Health, Other Health, Health, Clinical Trials, Cardiology, Gene, COVID-19, U.S. Securities and Exchange Commission, Cardiomyopathy, Arrhythmogenic cardiomyopathy, University, IND, NASDAQ, DCM, University of Texas Southwestern Medical Center, Degenerative disease, Heart failure, Cell, PKP2, Arrhythmia, AAV, Food, Safety, Securities Act of 1933, Patient, Security (finance), Survival, Clinical trial, Drug Quality and Security Act, Therapy, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Society, Disease, Investigational New Drug, Lists of diseases, Securities Exchange Act of 1934, ARVC, American Society of Gene and Cell Therapy, SERCA, HIV disease progression rates, Precision medicine, Annual general meeting, Model, Gladstone Institutes, Pharmaceutical industry, Vaccine, Tenaya

TN-401 is Tenayas gene therapy candidate being developed for the potential treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations.

Key Points: 
  • TN-401 is Tenayas gene therapy candidate being developed for the potential treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations.
  • These mutations are estimated to affect more than 70,000 patients in the U.S. alone.
  • Data being presented at ASGCT will detail the impact of a single dose of PKP2 gene therapy on arrhythmias, disease progression and survival in a Pkp2-deficient mouse model of ARVC.
  • The companys DWORF gene therapy is being developed for the potential treatment of genetic dilated cardiomyopathy (DCM).

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Gladstone Institutes, Arrhythmia, U.S. Securities and Exchange Commission, Arrhythmogenic cardiomyopathy, Model, Securities Exchange Act of 1934, Muscle tissue, Patient, Lists of diseases, AAV, IND, Therapy, Heart Rhythm, Investigational New Drug, COVID-19, Food, PKP2, Clinical trial, Securities Act of 1933, Precision medicine, University of Texas Southwestern Medical Center, Security (finance), Marketing, Cardiomyopathy, ARVC, NASDAQ, Degenerative disease, Industry, Drug Quality and Security Act, University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CA, Disease, Pharmaceutical industry, Tenaya

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced that it will present new preclinical data for its TN-401 PKP2 gene therapy program at the Heart Rhythm Societys upcoming annual Heart Rhythm 2022 meeting taking place in San Francisco, CA, and virtually.

Key Points: 
  • Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced that it will present new preclinical data for its TN-401 PKP2 gene therapy program at the Heart Rhythm Societys upcoming annual Heart Rhythm 2022 meeting taking place in San Francisco, CA, and virtually.
  • These data have been accepted for oral presentation as part of the Late-Breaking Clinical Trials: Late Breaking Science session taking place on Sunday, May 1, 2022.
  • TN-401 is Tenayas gene therapy candidate being developed for the potential treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations.
  • Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease.

Zeroing in on a New Treatment for Autism and Epilepsy

Retrieved on: 
Wednesday, April 27, 2022
Dravet syndrome, Gladstone Institutes, Mouse, Intellectual disability, Embryonic development, Life, DNA, SUDEP, Association, Media contacts database, Alzheimer's disease, ASO, Asos, Seizure, Death, Human, Cell, University of California, San Francisco, UC, Technology, SAN, Alzheimer's Association, Lists of diseases, Neurodegeneration, Autism, Therapy, Takeda Pharmaceutical Company, Tau, Multimedia, Epilepsy, University of California, San Francisco Fetal Treatment Center, Doctor of Philosophy, BrightFocus Foundation, Brain, National, Neuron, Communication, University, Risk, Science Translational Medicine, Neurology, Residential care, Pharmaceutical industry, Vaccine, Neuroscience, MD

SAN FRANCISCO, April 27, 2022 /PRNewswire/ -- Children with Dravet syndrome, a severe form of epilepsy that begins in infancy, experience seizures, usually for their entire life. They are at high risk of sudden unexpected death in epilepsy (SUDEP) and can also develop intellectual disability and autism. Available treatments typically fail to improve these symptoms.

Key Points: 
  • They are at high risk of sudden unexpected death in epilepsy (SUDEP) and can also develop intellectual disability and autism.
  • They also show that lowering tau is still effective in mice when the intervention is delayed until after their birth.
  • "They are also encouraging from a therapeutic perspective, since in humans, initiating treatment after birth is still more feasible than treating embryos in the womb."
  • However, defining the optimal timing for treatment initiation will be key, as the window of opportunity might be quite narrow."